论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
miR-596 抑制 Survivin 的表达,提高骨肉瘤细胞对分子靶向剂安罗替尼的敏感性
Authors Wang L, En H, Yang L, Zhang Y, Sun B, Gao J
Received 9 May 2019
Accepted for publication 31 July 2019
Published 21 August 2019 Volume 2019:12 Pages 6825—6838
DOI https://doi.org/10.2147/OTT.S215145
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Shreya Arora
Peer reviewer comments 3
Editor who approved publication: Dr Leo Jen-Liang Su
Background: Osteosarcoma (OSA), the most common primary bone malignancy, is characterized by a wide spectrum of complicated pathologies and frequent distal metastasis and causes death in adolescents and young adults worldwide. Antitumor drug treatment strategies include various cytotoxic chemotherapy drugs, while molecular targeted therapy for OSA is currently less used. The present work revealed the role played by the miR-596/Survivin axis in affecting the sensitivity of OSA cells to anlotinib, a novel molecular targeting agent.
Methods: By virtual screening, we found that miR-596 might target Survivin by using an online tool (miRDB). RNA levels of miR-596 and Survivin in clinical specimens were examined with qPCR. The effect of miR-596 on anlotinib’s antitumor effect was examined with MTT experiments, the subcutaneous tumor model, or the intramuscular tumor model.
Results: Overexpression of miR-596 via lentiviral particles repressed the protein level of Survivin in U2OS cells. Transfection of miR-596 enhanced the antitumor effect of anlotinib on U2OS cells or five cell lines derived from OSA patients.
Conclusion: miR-596 targets Survivin and enhances the antitumor effect of anlotinib on OSA cells.
Keywords: osteosarcoma cell, microRNAs, Survivin, molecular targeting agents, anlotinib